Evidence map›Paper›PMID 31101888›Full record

ReviewJournal of human hypertension2019

Blood pressure control in diabetes-the Indian perspective.

Vijay Viswanathan, T P Smina

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of human hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus.International journal of diabetes in developing countries · 2022
    Review
  4. Observational
  5. Article
  6. Spotlight on hypertension in the Indian subcontinent.Journal of human hypertension · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vijay ViswanathanM.V. Hospital for Diabetes and Prof. M. Viswanathan Diabetes Research Centre, (WHO Collaborating Centre for Research, Education and Training in Diabetes & IDF Centre for Excellence in Diabetes Care), No. 4, West Madha Church Street, Royapuram, Chennai, 600013, India. drvijay@mvdiabetes.com.
T P SminaM.V. Hospital for Diabetes and Prof. M. Viswanathan Diabetes Research Centre, (WHO Collaborating Centre for Research, Education and Training in Diabetes & IDF Centre for Excellence in Diabetes Care), No. 4, West Madha Church Street, Royapuram, Chennai, 600013, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A tremendous increase in the coexistence of diabetes and hypertension has been observed recently in India. Apart from lifestyle and genetic factors, socioeconomic status, age, gender, occupation and lack of awareness are also contributing to the tremendous increases in the prevalence of both the diseases. Hypertension has been long recognised as one of the major risk factors for chronic disease burden, morbidity and mortality in India, attributable to 10.8% of all deaths in the country. Even though microvascular complications are frequently linked to hyperglycaemia, studies have also proven the critical involvement of hypertension in the development of these co-morbidities. The co-occurrence of hypertension in diabetic patients considerably escalates the risks of coronary heart disease, stroke, nephropathy and retinopathy. The annual expenditure for diabetes for the Indian population was estimated to be 1541.4 billion INR ($31.9 billion) in 2010. The expense of diabetes care further escalates in the presence of complications or co-morbidities. Generally, a diabetic patient with hypertension spent an average of 1.4 times extra than a diabetic patient without hypertension. Even though diabetes and hypertension are considered as important risk factors for cardiovascular and chronic kidney diseases, the awareness about the prevention, treatment and control of these diseases remains alarmingly low in the developing countries like India. The healthcare system in India should focus on better hypertension screening and control, especially in diabetic patients, to minimise the burden of the dual epidemic.

Indexed as

Risk Reduction BehaviorAntihypertensive AgentsBlood GlucoseBlood PressureDiabetes MellitusHumansHypertensionHypoglycemic AgentsIndiaPrevalenceRisk AssessmentRisk FactorsTreatment OutcomeAntihypertensive AgentsBlood GlucoseHypoglycemic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.